ABOS · Insider Trading
Acumen Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by ABOS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Derrell Porter | Director | MIXED | −12,800 | −$54.37K |
| 2026-06-10 | Nathan B Fountain | Director | Sell | −6,400 | −$14.27K |
| 2026-06-05 | John A Stalfort III | Director | A | +35,500 | — |
| 2026-06-05 | Nathan B Fountain | Director | A | +35,500 | — |
| 2026-06-05 | Kimberlee C Drapkin | Director | A | +35,500 | — |
| 2026-06-05 | Jeffrey L. Ives | Director | A | +35,500 | — |
| 2026-06-05 | Derrell Porter | Director | A | +35,500 | — |
| 2026-06-05 | Laura Stoppel | Director | A | +35,500 | — |
| 2026-06-05 | RA Capital Healthcare Fund LP | Director | A | +177,500 | — |
| 2026-06-05 | George Golumbeski | Director | A | +35,500 | — |
| 2026-03-18 | Rajeev M. Shah | Director | A | +30,303,030 | +$100.00M |
| 2026-03-10 | Derek M Meisner | Chief Legal Officer & Corp Sec | MIXED | — | −$2.95K |
| 2026-03-03 | Derek M Meisner | Chief Legal Officer & Corp Sec | MIXED | — | −$10.91K |
| 2026-01-28 | Derek M Meisner | Chief Legal Officer & Corp Sec | MIXED | — | −$20.43K |
| 2026-01-23 | Daniel Joseph OConnell | Chief Executive Officer | Sell | −12,035 | −$21.99K |
| 2026-01-23 | Russell Barton | Chief Operating Officer | Sell | −2,777 | −$5.03K |
| 2026-01-23 | Eric Siemers | Chief Medical Officer | Sell | −3,226 | −$5.83K |
| 2026-01-23 | Derek M Meisner | Chief Legal Officer & Corp Sec | Sell | −8,934 | −$16.72K |
| 2026-01-23 | Matt Zuga | CFO & Chief Business Officer | Sell | −4,160 | −$7.61K |
| 2026-01-21 | Daniel Joseph OConnell | Chief Executive Officer | A | +299,800 | — |
| 2026-01-21 | Eric Siemers | Chief Medical Officer | A | +99,133 | — |
| 2026-01-21 | Matt Zuga | CFO & Chief Business Officer | A | +99,133 | — |
| 2026-01-21 | Derek M Meisner | Chief Legal Officer & Corp Sec | A | +99,133 | — |
| 2026-01-21 | Amy Schacterle | Chief Regulatory Officer | A | +84,600 | — |
| 2026-01-21 | Russell Barton | Chief Operating Officer | A | +84,600 | — |
| 2026-01-21 | James J. Doherty | President and CDO | A | +166,867 | — |
| 2026-01-12 | Matt Zuga | CFO & Chief Business Officer | Sell | −6,888 | −$12.51K |
| 2026-01-12 | Russell Barton | Chief Operating Officer | Sell | −3,530 | −$6.56K |
| 2026-01-12 | Derek M Meisner | Chief Legal Officer & Corp Sec | Sell | −50,659 | −$91.07K |
| 2026-01-12 | Daniel Joseph OConnell | Chief Executive Officer | Sell | −26,472 | −$46.95K |
| 2026-01-09 | James J. Doherty | President and CDO | Sell | −8,167 | −$15.15K |
| 2026-01-09 | Amy Schacterle | Chief Regulatory Officer | Sell | −1,097 | −$2.18K |
| 2026-01-07 | Eric Siemers | Chief Medical Officer | Sell | −10,834 | −$21.28K |
| 2026-01-07 | Russell Barton | Chief Operating Officer | Sell | −9,318 | −$18.32K |
| 2026-01-07 | Matt Zuga | CFO & Chief Business Officer | Sell | −14,905 | −$29.44K |
| 2026-01-07 | Daniel Joseph OConnell | Chief Executive Officer | Sell | −47,506 | −$94.18K |
| 2026-01-07 | Derek M Meisner | Chief Legal Officer & Corp Sec | Sell | −26,668 | −$52.69K |
| 2025-11-10 | George Golumbeski | Director | A | +50,000 deriv. | — |
| 2025-06-05 | Jeffrey L. Ives | Director | A | +12,800 | — |
| 2025-06-05 | Kimberlee C Drapkin | Director | A | +12,800 | — |
| 2025-06-05 | Nathan B Fountain | Director | A | +12,800 | — |
| 2025-06-05 | John A Stalfort III | Director | A | +12,800 | — |
| 2025-06-05 | Laura Stoppel | Director | A | +12,800 | — |
| 2025-06-05 | Derrell Porter | Director | A | +12,800 | — |
| 2025-06-05 | Rajeev M. Shah | Director | A | +64,000 | — |
| 2025-01-23 | Daniel Joseph OConnell | Chief Executive Officer | Sell | −12,619 | −$20.10K |
| 2025-01-23 | Derek M Meisner | Chief Legal Officer & Corp Sec | Sell | −3,418 | −$5.43K |
| 2025-01-23 | Matt Zuga | CFO & Chief Business Officer | Sell | −33,266 | −$56.62K |
| 2025-01-23 | Russell Barton | Chief Operating Officer | Sell | −2,914 | −$4.69K |
| 2025-01-23 | Eric Siemers | Chief Medical Officer | Sell | −3,219 | −$5.12K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rajeev M. Shah | Director | 19,103,785 | $40.12M |
| Daniel Joseph OConnell | Chief Executive Officer | 881,275 | $1.85M |
| John A Stalfort III | Director | 352,219 | $739.66K |
| Matt Zuga | CFO & Chief Business Officer | 304,924 | $640.34K |
| Eric Siemers | Chief Medical Officer | 255,371 | $536.28K |
| James J. Doherty | President and CDO | 220,900 | $463.89K |
| Russell Barton | Chief Operating Officer | 205,092 | $430.69K |
| Derek M Meisner | Chief Legal Officer & Corp Sec | 173,999 | $365.40K |
| Amy Schacterle | Chief Regulatory Officer | 92,303 | $193.84K |
| RA Capital Healthcare Fund LP | Director | 48,300 | $101.43K |
| Kimberlee C Drapkin | Director | 48,300 | $101.43K |
| Jeffrey L. Ives | Director | 48,300 | $101.43K |
| Laura Stoppel | Director | 48,300 | $101.43K |
| Nathan B Fountain | Director | 48,150 | $101.11K |
| George Golumbeski | Director | 35,500 | $74.55K |
| Derrell Porter | Director | 35,500 | $74.55K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ABOS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.